Results 41 to 50 of about 17,280 (228)

Surgical outcome of atypical subtrochanteric and femoral fracture related to bisphosphonates use in osteoporotic patients with or without teriparatide treatment

BMC Musculoskeletal Disorders, 2017
Background Atypical subtrochanteric fracture and femoral fracture have been considered to be rare complications related to long-term bisphosphonates use. A reduced bone turnover rate may lead to delayed bone healing.
Wen-Ling Yeh, Chun-Yi Su, Chia-Wei Chang, Chien-Hao Chen, Tsai-Sheng Fu, Lih-Huei Chen, Tung-Yi Lin   +6 more
doaj   +1 more source

Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO. [PDF]

, 2017
Antiosteoporotic drugs are recommended in patients with fragility fractures and in patients considered to be at high fracture risk on the basis of clinical risk factors and/or low bone mineral density.
Aubry-Rozier, B., Birkhäuser, M., Bischoff-Ferrari, H.A., Ferrari, S., Frey, D., Kressig, R.W., Lamy, O., Lippuner, K., Meier, C., Stute, P., Suhm, N., Uebelhart, B.   +11 more
core   +4 more sources

Evaluation of Teriparatide for Treatment of Osteoporosis in Four Patients with Cystic Fibrosis: A Case Series

Case Reports in Endocrinology, 2014
Introduction. Bone disease is a common complication of cystic fibrosis (CF). To date, there have been no reports on the effectiveness of teriparatide, recombinant human parathyroid hormone, to treat CF-related bone disease. Case Presentation.
Oranan Siwamogsatham, Kelly Stephens, Vin Tangpricha   +2 more
doaj   +1 more source

Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment

Bone Reports, 2020
Introduction: Osteoporosis is one of the serious adverse effects associated with glucocorticoid therapy. Although bisphosphonates have been used for glucocorticoid-induced osteoporosis (GIO), some patients have shown an inadequate response. In such cases,
Yasuaki Hirooka, Yuji Nozaki, Asuka Inoue, Jinhai Li, Toshihiko Shiga, Kazuya Kishimoto, Masafumi Sugiyama, Koji Kinoshita, Masanori Funauchi, Itaru Matsumura   +9 more
doaj   +1 more source

Bone texture modifications during bone regeneration and osteocyte cell-signaling changes in response to treatment with Teriparatide [PDF]

, 2016
Bone texture modifications during bone regeneration and osteocyte cell-signaling changes in response to treatment with ...
CAVANI, Francesco, Checchi, Marta, FERRETTI, Marzia, PALUMBO, Carla, SMARGIASSI, ALBERTO   +4 more
core   +1 more source

Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis

Arthritis &Rheumatology, Accepted Article.
Background Transition from long‐term denosumab to PTH‐analogs or romosozumab might expose patients to the risk of the so‐called rebound phenomenon. Adding romosozumab to denosumab might represent an option in patients experiencing a fracture while on denosumab.
Giovanni Adami, Francesco Pollastri, Angelo Fassio, Filippo Montanari, Anna Piccinelli, Camilla Benini, Emma Pasetto, Carmen Dartizio, Davide Gatti, Maurizio Rossini, Ombretta Viapiana   +10 more
wiley   +1 more source

An observational study to assess back pain in patients with severe osteoporosis treated with teriparatide versus antiresorptives: An Indian subpopulation analysis

Indian Journal of Endocrinology and Metabolism, 2015
Background: One year, prospective, observational study in an Indian subpopulation to assess back pain in patients with severe osteoporosis treated with teriparatide or antiresorptives in a clinical setting. Materials and Methods: One hundred and nineteen
Harvinder Chhabra, Rajesh Malhotra, Sunil Marwah, Bharat Dave, Kyoungah See, Simrat Sohal, Sirel Gurbuz   +6 more
doaj   +1 more source

Parathyroid hormone 1-34 and skeletal anabolic action: The use of parathyroid hormone in bone formation [PDF]

, 2017
Intermittently administered parathyroid hormone (PTH 1-34) has been shown to promote bone formation in both human and animal studies. The hormone and its analogues stimulate both bone formation and resorption, and as such at low doses are now in clinical
Blunn, G, Bostrom, M, Briggs, T, Coathup, M, Osagie-Clouard, L, Sanghani, A   +5 more
core   +1 more source

Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan’s National Claims Database

Clinical Pharmacology &Therapeutics, EarlyView.
Disproportionality analyses suggested a cardiovascular risk signal for romosozumab, while statistically significant associations were not found in the real‐world database studies. Therefore, a larger comparative study was necessary to examine this signal.
Hotaka Maruyama, Eiko Iwasa, Shinya Watanabe, Tomoaki Hasegawa, Kazuhiro Kajiyama, Taihei Tanaka   +5 more
wiley   +1 more source

Risk factor identification and prevention of osteoporosis in the primary care setting [PDF]

, 2006
On one of her visits, MB Borg, a 54 year old lady, showed concern about her risk of developing osteoporosis. Lately, she had been listening to a series of radio and TV programmes on this matter where particular emphasis was put on bone density scans. She
De Gabriele, Patricia
core